ACET
Price
$0.76
Change
-$0.02 (-2.56%)
Updated
Jul 25 closing price
Capitalization
63.81M
10 days until earnings call
SYRE
Price
$17.79
Change
+$0.19 (+1.08%)
Updated
Jul 25 closing price
Capitalization
1.07B
4 days until earnings call
Interact to see
Advertisement

ACET vs SYRE

Header iconACET vs SYRE Comparison
Open Charts ACET vs SYREBanner chart's image
Adicet Bio
Price$0.76
Change-$0.02 (-2.56%)
Volume$123.2K
Capitalization63.81M
Spyre Therapeutics
Price$17.79
Change+$0.19 (+1.08%)
Volume$841.4K
Capitalization1.07B
ACET vs SYRE Comparison Chart in %
Loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACET vs. SYRE commentary
Jul 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a StrongBuy and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 27, 2025
Stock price -- (ACET: $0.76 vs. SYRE: $17.79)
Brand notoriety: ACET and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACET: 30% vs. SYRE: 149%
Market capitalization -- ACET: $63.81M vs. SYRE: $1.07B
ACET [@Biotechnology] is valued at $63.81M. SYRE’s [@Biotechnology] market capitalization is $1.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 2 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • ACET’s FA Score: 2 green, 3 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, ACET is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • ACET’s TA Score: 5 bullish, 5 bearish.
  • SYRE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, SYRE is a better buy in the short-term than ACET.

Price Growth

ACET (@Biotechnology) experienced а +0.20% price change this week, while SYRE (@Biotechnology) price change was +9.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.60%. For the same industry, the average monthly price growth was +17.32%, and the average quarterly price growth was +27.29%.

Reported Earning Dates

ACET is expected to report earnings on Aug 06, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+7.60% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1.07B) has a higher market cap than ACET($63.8M). ACET YTD gains are higher at: -20.894 vs. SYRE (-23.582). ACET has higher annual earnings (EBITDA): -110.82M vs. SYRE (-214.36M). SYRE has more cash in the bank: 565M vs. ACET (150M). SYRE has less debt than ACET: SYRE (0) vs ACET (16.2M). ACET (0) and SYRE (0) have equivalent revenues.
ACETSYREACET / SYRE
Capitalization63.8M1.07B6%
EBITDA-110.82M-214.36M52%
Gain YTD-20.894-23.58289%
P/E RatioN/A1.68-
Revenue00-
Total Cash150M565M27%
Total Debt16.2M0-
FUNDAMENTALS RATINGS
ACET vs SYRE: Fundamental Ratings
ACET
SYRE
OUTLOOK RATING
1..100
3115
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
74
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
5154
P/E GROWTH RATING
1..100
1985
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACET's Valuation (30) in the Medical Distributors industry is somewhat better than the same rating for SYRE (74) in the Pharmaceuticals Major industry. This means that ACET’s stock grew somewhat faster than SYRE’s over the last 12 months.

ACET's Profit vs Risk Rating (100) in the Medical Distributors industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that ACET’s stock grew similarly to SYRE’s over the last 12 months.

ACET's SMR Rating (97) in the Medical Distributors industry is in the same range as SYRE (98) in the Pharmaceuticals Major industry. This means that ACET’s stock grew similarly to SYRE’s over the last 12 months.

ACET's Price Growth Rating (51) in the Medical Distributors industry is in the same range as SYRE (54) in the Pharmaceuticals Major industry. This means that ACET’s stock grew similarly to SYRE’s over the last 12 months.

ACET's P/E Growth Rating (19) in the Medical Distributors industry is significantly better than the same rating for SYRE (85) in the Pharmaceuticals Major industry. This means that ACET’s stock grew significantly faster than SYRE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETSYRE
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
87%
Bullish Trend 3 days ago
83%
MACD
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
82%
Bullish Trend 5 days ago
85%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 17 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FVRMX25.750.32
+1.26%
Franklin Mutual Small-Mid Cap Val Adv
FDGKX42.540.21
+0.50%
Fidelity Dividend Growth K
EQNRX23.180.08
+0.35%
MFS Equity Income R1
FVLCX19.810.02
+0.10%
Fidelity Advisor Value Leaders C
LISIX16.52-0.02
-0.12%
Lazard International Strategic Eq Instl

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with SYRE. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
-1.90%
SYRE - ACET
42%
Loosely correlated
+1.08%
RGNX - ACET
42%
Loosely correlated
-1.86%
ARWR - ACET
40%
Loosely correlated
-3.20%
IPSC - ACET
40%
Loosely correlated
-5.17%
INBX - ACET
39%
Loosely correlated
+0.04%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with IDYA. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+1.08%
IDYA - SYRE
60%
Loosely correlated
-1.33%
BEAM - SYRE
58%
Loosely correlated
+3.68%
CGON - SYRE
57%
Loosely correlated
-0.15%
XNCR - SYRE
57%
Loosely correlated
N/A
KRYS - SYRE
54%
Loosely correlated
-1.59%
More